All In Biotech

Drug Trial Radar · NCT01194934

NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers

A Single Center, Open-label, Repeated Dose, Phase I Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics and the Effect on Mobilization of Hematopoietic Stem Cells of NOX-A12 Alone and in Combination With Filgrastim

Last checked: Nov 19, 2026Latest source record: Jun 26, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Aug 2010

Primary completion

Jan 2011

Study completion Jan 2011

Sponsor

Lead sponsor
TME Pharma AGIndustry
Sponsor type
Industry
First posted
Sep 3, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is the second clinical study of NOX-A12. This study intends to provide information on the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of repeated intravenous doses of NOX-A12 (2.0 and 4.0 mg/kg/d) alone and to compare the mobilization of hematopoietic stem cells (HSC) obtained with NOX-A12 alone with that obtained in combination with filgrastim in healthy subjects. A single center, open-label, repeated dose study design is selected to best address the study objectives.The results from this study will establish the basis for further development of NOX-A12 in lymphoma patients undergoing autologous hematopoietic stem cell transplantation

Conditions

  • Hematopoietic Stem Cell Transplantation

Interventions

  • NOX-A12Drug

    4 mg/kg daily IV for 5 days

  • NOX-A12Drug

    2 mg/kg daily IV for 5 days

  • FilgrastimDrug

    5 µg/kg SC daily for 5 days

  • NOX-A12 in combination with FilgrastimDrug

    Safe and efficacious dose regimen according to results of groups A and B

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the safety and tolerability of repeated doses of NOX-A12 alone and in combination with filgrastim in healthy subjects.Time frame: 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Charité Research Organisation GmbH

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.